Albumex (human albumin) / CSL Behring - LARVOL DELTA

Efficacy and Safety of Outpatient Human Albumin Infusions in Patients with Decompensated Cirrhosis and Ascites: A Real-World Cohort Study from Australia (APASL 2025) - "Inclusion criteria included patients with cirrhosis who had commenced regular HA (Albumex20 or Alburex20, CSL Ltd, Australia) at least 6 months prior to data collection. This study represents the largest real-world cohort of patients with cirrhosis receiving regular HA infusions outside Italy. While comorbidities and alcohol consumption remain prevalent, the rates of paracentesis and inpatient admissions are low among this decompensated population. Despite recent safety concerns, only two minor adverse events were recorded."

Clinical • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Hematological Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Pain • Renal Disease • Respiratory Diseases • Thrombosis

20% Human Albumin Solution Fluid Bolus Administration Therapy in Patients after Cardiac Surgery-II (ANZCTR) - P2 | N=480 | Completed | Sponsor: Austin Health | Recruiting ➔ Completed

Surgery • Trial completion • Cardiovascular